Aligos Therapeutics, Inc.
ALGS
$4.08
$0.092.26%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -82.15M | -19.26M | 5.06M | -34.86M | -27.89M |
| Total Depreciation and Amortization | 671.00K | 667.00K | 610.00K | 674.00K | 775.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 63.47M | 1.67M | -29.28M | 16.94M | 4.75M |
| Change in Net Operating Assets | -390.00K | -3.18M | 4.11M | -5.49M | -293.00K |
| Cash from Operations | -18.40M | -20.10M | -19.49M | -22.75M | -22.66M |
| Capital Expenditure | -28.00K | -26.00K | -7.00K | -69.00K | -7.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.00M | 10.42M | 40.00M | -88.57M | 0.00 |
| Cash from Investing | 19.97M | 10.40M | 39.99M | -88.64M | -7.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -43.00K | -5.00K | -16.00K | -19.00K | -4.00K |
| Issuance of Common Stock | 140.00K | 1.00K | 297.00K | -- | 17.53M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 70.41M |
| Cash from Financing | 97.00K | -4.00K | 281.00K | -19.00K | 87.94M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.67M | -9.71M | 20.78M | -111.41M | 65.27M |
